Avecho Biotechnology (AVE) Q1 2026 TU earnings summary

Executive summary

• Exceeded recruitment target for Phase III insomnia trial, randomising 244 patients, 16% above plan, enhancing statistical power for interim analysis.

• Interim analysis read-out remains on track for June 2026, with an independent Data Monitoring Board (DMB) overseeing data integrity.

• Commercial partnership with Sandoz AG secured for Australia, including milestone payments and tiered royalties on net sales.

• Strengthened patent position in the US and EU, supporting global commercialisation efforts.

Financial highlights

• Cash balance at 31 March 2026 was $4.3 million.

• Operating cash outflows for the quarter were $578K, partially offset by $184K in customer receipts.

• $493K invested in research and development during the quarter, focused on the Phase III trial.

• Payments to related parties totaled $66K for the quarter.

Outlook and guidance

• Interim analysis in June 2026 is expected to de-risk the program and support licensing discussions outside Australia.

• Cash runway estimated at 4.89 quarters as of 31 March 2026, supporting ongoing development and operations.

• Positive interim results could accelerate commercialisation and value creation.